Recruiting studies: High Risk Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Phase 2 · 1 location(s) · Ivan de Kouchkovsky, MD · NCT06384222 Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05956639 A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patien
Phase 2/Phase 3 · 2 location(s) · Shanghai Jiao Tong University School of Medicine · NCT03258320 SRT Versus SRT+ADT in Prostate Cancer
Phase 3 · 1 location(s) · Marco Lorenzo Bonu · NCT05019846 High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Phase N/A · 1 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT06982469 High Intensity Focused Ultrasound in Prostate Cancer
Phase 2 · 1 location(s) · University of Florida · NCT06402357 High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Phase 2 · 17 location(s) · VA Office of Research and Development · NCT05011383 Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT07182279 Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
Phase N/A · 9 location(s) · Xijing Hospital · NCT07553780 In Vivo Dosimetry for Brachytherapy Study
Phase N/A · 1 location(s) · East and North Hertfordshire NHS Trust · NCT06863090 Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: Th
NA · 4 location(s) · Fred Hutchinson Cancer Center · NCT05918263 This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497 The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Uppsala University · NCT06446401 ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT07407608 Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Phase 3 · 18 location(s) · ABX advanced biochemical compounds GmbH · NCT06122584 Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Pati
Phase 2 · 1 location(s) · Samsung Medical Center · NCT06461793 PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confi
Phase N/A · 3 location(s) · Istituto Clinico Humanitas · NCT06949254 Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI
Phase 2 · 3 location(s) · Ain Shams University · NCT07693075 Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
NA · 1 location(s) · University Health Network, Toronto · NCT06508567 Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Ly
NA · 1 location(s) · Ruijin Hospital · NCT07115992 Training for Men Undergoing Androgen Deprivation Therapy.
NA · 1 location(s) · The Swedish School of Sport and Health Sciences · NCT06449664 Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Phase 2 · 4 location(s) · Martin T. King, MD, PhD · NCT07393867 To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopatho
Phase N/A · 4 location(s) · XEOS Medical · NCT06970275 Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT06470750 Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer
NA · 1 location(s) · Center Eugene Marquis · NCT07189598 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Phase 2 · 1 location(s) · Maria Sklodowska-Curie National Research Institute of Oncolo · NCT06449781 Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
Phase N/A · 1 location(s) · Anhui Medical University · NCT07112599 24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
NA · 1 location(s) · IRCCS San Raffaele · NCT05936736 Vitamin D for Prostate Endocrine Therapy
Phase 3 · 51 location(s) · University of Rochester · NCT05838716 PSMA PET Response Guided SabR in High Risk Pca
Phase 1 · 2 location(s) · University of Texas Southwestern Medical Center · NCT06044857

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.